Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus UCERIS.
CELESTONE SOLUSPAN vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Plasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection).
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category C
Category C
Corticosteroid
Corticosteroid